FIELD: biotechnology.
SUBSTANCE: invention relates to a stable composition containing from about 10 mg/ml to about 200 mg/ml of an anti-TIGIT antibody or an antigen-binding fragment thereof, from about 5 mm to about 20 mm of L-histidine buffer, from about 6 % to about 8% (w/v) of sucrose, about 0.01% to about 0.10% (w/v) of polysorbate 80, about 1 mM to about 20 mM of L-methionine, and from about 10 mg/ml to about 200 mg/ml of an anti-PD1 antibody or antigen binding fragment thereof, where the formulation is a co-formulation and where pH of the stable formulation is from 5.3 to 6.2.
EFFECT: invention is effective for the treatment of malignant tumors and for the treatment of chronic infections.
19 cl, 8 dwg, 6 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
| ANTIBODIES AGAINST GUCY2c AND THEIR USE | 2019 |
|
RU2812113C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTIBODIES TO PD-1 AND COMPOSITIONS | 2016 |
|
RU2750675C1 |
